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Simrit Parmar, Marcos de LimaAllogeneic hematopoietic stem cell transplantation remains the only curative option for myelodysplastic syn-
drome, but patients with this disease are often older and frail, and treatment-related mortality and morbidity
is a major obstacle to be overcome. Treatment of MDS is likely to benefit from the major lines of investigation
in the field of allogeneic transplantation, especially interventions postulated to decrease the morbidity of the
procedure, such as less toxic preparative regimens. In this review we summarize current recommendations
and controversies surrounding HSCTas well as integration of the novel therapeutic agents in the peritrans-
plant period.
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erogeneous group of clonal hematopoietic stem cell
(HSC) disorders characterized by peripheral cytope-
nias, hypercellular bone marrow (BM), and increased
morbidity and mortality because of evolution to acute
myelogenous leukemia (AML) or BM failure [1]. MDS
is a disease of the elderly, with the median age at diag-
nosis in the eighth decade of life. Allogeneic hemato-
poietic stem cell transplantation (HSCT) remains the
only curative option for this disease, despite new ther-
apeutic interventions. But, the discrepancy between
the age of the ‘‘regular’’ MDS patients and those who
ultimately receive a transplant indicates that a signifi-
cant selection bias exists, and HSCT results should
be interpreted with that in mind [1,2]. The reduced
transplantation toxicity over the last decade has led
to an increase in the upper age limit of HSCT recipi-
ents, thereby potentially benefiting more patients with
MDS. Several questions remain unanswered, includ-
ing transplantation timing and proper integration
with newer therapies. In addition, the success of allo-
geneic HSCT is often limited by graft-versus-host-
disease (GVHD) and relapse. Here, we review some
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Age is a major deciding factor, and most patients
under the age of 60 years are likely to be considered
for transplantation before older patients. Disease stage
is the other major determinant. The International
Prognostic Scoring System (IPSS) categories interme-
diate-2 or high-risk (scoring based on cytopenias,
cytogenetics, and blast percentage) are generally con-
sidered candidates for earlier HSCT [3,4]. However,
the IPSS and World Health Organization (WHO)
classifications may underestimate the impact of trans-
fusion dependence (both platelets and red blood cells)
in any given category [5,6]. The WHO’s Prognostic
Scoring System (WPSS) represents one effort to
improve risk stratification [7].
Cutler et al. [3] reported a retrospective registry-
based analysis indicating that upfront transplantation
was associated with a greater number of added life
years for intermediate- 2 and high-risk IPSS patients.
Delaying HSCT was the best strategy for patients in
other risk categories. These conclusions were reached
in a young cohort receiving HLA-identical sibling
HSCT and must be interpreted in that context, how-
ever. In general, young patients with less advanced
disease have better transplantation outcomes than
patients with more aggressive disease [8]. Treatment-
related mortality (TRM) is a major cause of failure
after HSCT and must be taken into consideration
when making a decision regarding transplantation in
a patient with low-risk disease.
The issue of low-risk disease is far from resolved,
however. Recent data from the Gruppo Italiano
Trapianto di Midollo Osseo suggest that lower-risk pa-
tients (according to the WHO classification system) didS37
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blasts had a 5-year overall survival (OS) of only 25%-
28% [9]. The 5-year OS was 80% in refractory anemia
(RA), 57% in RA with multilineage dysplasia, 51% in
RA with excess blasts (RAEB)-1, 28% in RAEB-2, and
25% in acute leukemia arising from MDS. In another
series that included 374 patients with low-risk MDS
(median age, 39 years), the 4-year OS was 52% [10].
Furthermore, no survival difference was seen between
HLA-identical sibling and HLA-matched unrelated
donor (MUD) transplants, and improved survival and
lower TRM were associated with transplantations per-
formed early after diagnosis [10].
An American Society for Blood and Marrow
Transplantation 2009 consensus paper [11] recom-
mended early HSCT for patients with an IPSS score
of intermediate-2 or high-risk at diagnosis and a suit-
able donor who meet the transplantation center’s eligi-
bility criteria, as well as for selected patients with
lower-risk disease at diagnosis who have poor prog-
nostic features (eg, older age, refractory cytopenia,
transfusion dependence). The use of newer prognostic
tools, such as flow cytometry and molecular markers, is
expected to improve our ability to select patients based
on disease characteristics. Newer risk models that
identify covariates affecting outcomes across medical
and HSCT therapies and individual risk factors (such
as comorbidities) also should be considered when
weighing the decision of whether to proceed to alloge-
neic HSCT.AGE AND COMORBIDITIES
Age per se is not considered a contraindication to
HSCT (at least up to age 65-75 years); however, aging
is associated with disease refractoriness and poorer
characteristics, and also with the development of
comorbid conditions. It is intuitive to assume that di-
abetes and coronary artery disease, for example, will
increase the possibility of TRM. MDS, on the other
hand, is likely the greatest threat to survival of a pa-
tient with this diagnosis, a fact that must be consid-Table 1. Role of Induction Chemotherapy before Transplantation i
Reference
Pretransplantation
induction therapy CR RF
Nakai et al., 2005 [19] Yes, 188; no, 9 43%/0 4-year
28.9%
Oosterveld et al., 2002 [24] Yes, 184; no, 215 54%/63%
Scott et al., 2005 [20] Yes, 33; no, 92 54%/22% 3-year RF
26% (P
de Witte et al., 1990 [61] Yes, 34; no, 44 47%/0 35%/
Warlick e al., 2009 [21] Yes, 42%; no, 58% 6%/0 54%/
Castro-Malaspina
et al., 2008 [22]
Yes, 36; no, 13 61%/0 3-year
respond
untreat
failu
MDS indicates myelodysplastic syndrome; CR, complete remission; RFS, relapered when weighing comorbidities in the decision to
proceed to transplantation. The HSCT-specific co-
morbidity index (HCT-CI) score may be used to
stratify risk groups, although it has not yet been
used systematically in a prospective fashion [12].
Both HCT-CI and Karnofsky performance status
have been reported to be independent predictors of
outcome in allogeneic HSCT with both conventional
(high-dose) conditioning and reduced-intensity con-
ditioning (RIC) [13,14].
A pretransplantation serum ferritin level. 1000mg/
L has been shown to have an adverse impact on OS as
well as other outcomes of MDS in general, specifically
after HSCT, regardless of blood transfusion burden
[15]. Other adverse consequences of iron overload in
the HSCT setting may include increased risk of septice-
mia, invasive fungal infections, and sinusoidal obstruc-
tion syndrome [16,17]. At present, it is unclear
whether iron chelation will reduce these risks for
MDS patients; prospective clinical trials are needed to
clarify this issue [18].ROLE OF TREATMENT BEFORE
TRANSPLANTATION AND THE IMPACTOF
CYTOREDUCTION
In the absence of randomized prospective trials,
the value of induction chemotherapy before allogeneic
HSCT remains unresolved (Table 1). Nakai et al. [19]
compared the outcomes of 283 adults with MDS
(76%) or secondary AML (sAML) who received (n 5
188) or did not receive (n5 95) induction chemother-
apy before HLA-identical sibling donor HSCT and
found no difference in survival, with 5-year OS proba-
bilities of 54% and 57%, respectively. Similarly, Scott
et al. [20] failed to show a clear survival advantage for
a cohort of patients in Seattle studied retrospectively
that received induction chemotherapy before HSCT,
although the risk of relapse was somewhat reduced in
these patients. The intrinsic bias with retrospective
analyses of this nature is that patients selected for
chemotherapy likely were different from those whon MDS
S OS Relapse Follow-Up
RFS:
/17.3%
5-year OS: 54%/
57% (P 5 .81)
27.6%/26.2% 36.5 months
4-year OS:
34.4%/25.5%
Median,3.6 years/
3.0 years
S: 13%/
5 .26)
42%/28%
25% 23%/22%
10% 53%/35% 18%/35% 2.4 years
RFS:
ers, 45%;
ed, 15%;
res, 0
3-year OS:
responders, 54%;
untreated, 31%;
failures, 0
30%/38% 77 months
se-free survival; OS, overall survival.
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of having higher-risk disease, with more blasts, etc),
making comparisons very difficult.
Conversely, being in remission at the time of
HSCT may favorably affect relapse and TRM rates
(keeping in mind that complete remission [CR] with
any treatment is achieved in only a small minority of pa-
tients with MDS). Warlick et al. [21] studied 84
patients undergoing allogeneic HSCT while in remis-
sion and found a 1-year cumulative incidence cumula-
tive index (CI) of relapse of 18%, compared with 35%
in those undergoing transplantation with active dis-
ease. In a retrospective analysis of 49 MDS/AML pa-
tients treated with T cell7–depleted grafts, the 2-year
CI of TRM was 23% for patients with responsive dis-
ease, 38% for untreated patients, and 40% for patients
with refractory disease [22]. Oran et al. [23] also noted
the benefit of minimal tumor burden at the time of
transplantation in patients with high-risk MDS/AML
receiving RIC HSCT. CR at HSCT was associated
with a day-100 TRM of 0 and a 2-year TRM of 20%.
Estimates of 2-year OS were 66% for patients in remis-
sion, 40% for those with active disease without circu-
lating blasts, and 23% for those with circulating
blasts [23]. Considering the lack of prospective studies,
the decision to use pre-HSCT induction therapy
should be made on an individual basis. Classic AML-
type chemotherapy is being used with decreasing fre-
quency as other drugs become available, although
whether this approach will change the long-term out-
come is unclear [11,24].THE ROLE OF PERITRANSPLANTATION
TREATMENTWITH NOVEL AGENTS
Treatment with azacitidine has been shown to pro-
long survival in patients with MDS [25]. Whether
treatment with hypomethylating agents before
transplantation will influence post-HSCT survival,
toxicities, or other outcome parameters is unclear,
however. Field et al. [26] reported the effect of pre-
transplantation 5-azacytidine in 30 patients who re-
ceived a median of 4 cycles of the drug compared
with 24 patients who received no treatment before
HSCT. The 1-year estimates of OS, relapse-free sur-
vival (RFS), and CI of relapse were 47%, 41%, and
20%, respectively, for the 5-azacitidine–treated
patients and 60%, 51%, and 32% for the untreated pa-
tients. These findings suggest a trend toward
decreased early relapse, but not improved survival, in
patients receiving pre-HSCT 5-azacitidine [26]. In
an M.D. Anderson Cancer Center (MDACC) retro-
spective analysis of 17 MDS patients (median age, 55
years) who underwent allogeneic HSCT (12 with sib-
ling donors and 5 with MUD) after previous therapy
with decitabine, no unexpected toxicities wereobserved, and 11 patients were alive in CR at a median
follow-up of 12 months [27]. Thus, hypomethylating
agents may be of value in stabilizing the disease with-
out adding toxicity to HSCT, thereby allowing time
for patients to reach transplantation, possibly with
downstaged disease, similar to what is expected with
conventional chemotherapy.
In the MDACC experience, however, the out-
comes of patients who fail to respond to hypomethy-
lating agents are dismal [28]. Whether or not HSCT
can salvage patients who fail to respond to therapy
with decitabine or azacitidine is largely unknown;
thus, timely detection of such patients and early discus-
sion of allogeneic HSCT are important. Another unre-
solved question regarding these agents pertains to the
responders: Should a patient be considered for HSCT
at the time of best response or when the disease no
longer responds or progresses? These and related
questions can be answered only by well-conducted,
prospective clinical studies.
We have hypothesized that azacitidine may have
immunomodulatory effects (such as increased expres-
sion of tumor antigens) that could potentially increase
the graft-versus-leukemia (GVL) effect after HSCT.
Low doses actually may be as effective as standard
doses [29] and be better tolerated after HSCT. A phase
I trial identified a 5-azacytidine dose of 32 mg/m2/day
for 5 days in 28-day cycles as safe and well tolerated
when started during week 6 or 7 post-HSCT [30].
Preliminary results indicated prolonged RFS for re-
lapsed and refractory MDS/AML patients compared
with historical controls. We have kept patients on
maintenance therapy for up to 2 years with low-dose
azacitidine with no unexpected toxicities. Given this
promising preliminary experience, a Phase III study
comparing maintenance with azacitidine versus stan-
dard of care (ie, no maintenance) for MDS and AML
patients at high risk for relapse has been initiated at
MDACC [31].AUTOLOGOUS ANDALLOGENEIC
TRANSPLANTATIONS
Most studies comparing autologous and alloge-
neic HSCT reflect the practices of the previous de-
cade, and as such illustrate the trade-off between
higher TRM and lower relapse rates with allogeneic
HSCT. A multicenter study compared allogeneic
and autologous HSCT as postconsolidation therapy
for patients with advanced MDS, secondary AML,
or chronic myelomonocytic leukemia (CMML), de-
pendent on the availability of an HLA-matched re-
lated donor [32]. Four-year RFS and OS were 31%
and 36% for patients with a donor and 27% and
33% for those without a donor, although several pa-
tients did not receive the autologous transplant as
Table 2. Comparison of Related and Unrelated Donor Transplantations for MDS
Reference Donor Type NRM RFS OS aGVHD Follow-Up
Deeg et al., 2002 [37] 45 related;
64 unrelated
Day 100/3 years:
related, 12%/28%;
unrelated, 13%/30%
3-year RFS: related,
56%; MUD, 9%;
mismatched unrelated, 29%
Related, 64%; MUD,
68%; mismatched
unrelated, 100%
Ho et al., 2004 [38] 24 related;
38 unrelated
Day 100: 0%/5%;
11%/21%
1-year RFS: 61%/59% 1-year OS:
73%/71%
1-year grade III/IV
aGVHD: 17%/23%
524 days/ 420 days
Jurado et al., 2002 [39] 20 related;
40 unrelated
35%/55% 3-year RFS: 35%/20% Grade II-IV aGVHD:
85%/83%
54 months
Hallemeier et al., 2006 [40] 21 related;
30 unrelated
3-year TRM: 31%/51% 3-year relapse
risk:/31%/46%
3-year OS:
48%/30%
Grade II-IV
aGVHD: 11%/37%
3.7 years
Nakamura et al., 2007 [41] 19 related;
24 unrelated
2-year TRM:
31.6%/37.5%
Relapse risk: 38.5%/7% 2-year OS:
47.4%/58.3%
38 months
Kroger et al., 2003 [42] 19 related;
18 unrelated
45%/12% (P 5 .03) 3-year RFS: 51%/25% 3-year OS:
45%/31%
20 months
MDS indicates myelodysplastic syndrome; NRM, nonrelapse mortality; RFS, relapse-free survival; OS, overall survival; aGVHD, acute graft-versus-host
disease.
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Bone Marrow Transplant (EBMT) group have inves-
tigated the use of autologous HSCT for MDS and
treatment-related AML. In a large series of 184
MDS patients who underwent induction chemother-
apy, 100 patients achieved CR and were to receive fur-
ther therapy with allogeneic or autologous HSCT,
based on donor availability [32]. Twenty-eight pa-
tients received an allograft, and 36 patients without
a donor received an autograft while in first CR. The
4-year RFS rate was 31% in the first group and
27% in the second group, and the respective 4-year
survival rates from CR were 36% and 33% [32]. A
study of 65 patients who underwent autologous
HSCT reported a CI of relapse of 58% and a TRM
of 2% [33].
De Witte et al. [34] reported a registry analysis of
allogeneic unrelated or related donor and autologous
HSCT showing a 3-year RFS of 25%, 36%, and
30%, respectively, and a relapse rate of 41%, 36%,
and 58%, respectively. A more recent retrospective
study of 593 patients compared unrelated donor
HSCT with autologous HSCT and reported the
following 3-year OS rates: unrelated donor in first
CR, 50%; autologous HSCT in first CR, 41%; and
unrelated donor untreated, 40% (P 5 .01), with
a higher relapse rate for autologous transplantations
(62%) [35]. Although autologous HSCT may be
feasible in a small proportion of patients with MDS,
it is associated with a higher relapse rate and pro-
longed cytopenias and thus should be pursued only
within clinical trials [36].
High-resolution HLA typing and general im-
provements in supportive care have led to a perceived
equivalence in outcomes after unrelated and related
donor HSCT [37-42] (Table 2). Deeg et al. [37] re-
ported the Seattle experience in 109 MDS patients.
The 3-year RFS was 56% for related transplant recip-
ients and 59% for unrelated transplant recipients. No
difference in TRM was seen at 100 days (12% vs 13%)
or at 3 years (28% vs 30%). Ho et al. [38] studied 62MDS patients undergoing RIC HSCT with fludara-
bine (Flu), busulfan (Bu), and alemtuzumab condition-
ing and found a 1-year OS of 73% for sibling donor
HSCT and 71% for unrelated transplant recipients,
with a respective RFS of 61% and 59%.ALTERNATIVE STEM CELL SOURCES
Relatively few patients have received cord blood
(CB) or haploidentical HSCT for MDS [43]. A pro-
spective study from Japan using conventional dose-
conditioning CB transplants for 13 adult patients
with advanced MDS found a 2-year RFS of 76%
[44]. Three patients relapsed, 1 patient failed to en-
graft, and 10 patients were alive in CR at 171-1558
days after transplantation. Parikh et al. [45] reported
23 pediatric MDS patients (median age, 11 years)
treated with total body irradiation (TBI)-based con-
ditioning regimens before transplantation with 4 or
5 of 6 HLA antigen-matched CB units; with a median
follow up of 5.3 years, the probability of RFS at 1
year and 3 years was 69.6% and 60.9%, respectively.
The grafts contained a median of 4.0  107 total nu-
cleated cells (TNCs)/kg, and the CI of neutrophil
and platelet engraftment was 91.3% and 69.6%, re-
spectively. Ooi [46] reported data on 22 adult MDS
patients (median age, 40 years) who received single-
unit CB transplants containing a median TNC dose
of 2.43  107/kg. The median time to myeloid en-
graftment was 23 days. Of the 22 patients, 17 were
alive and disease-free at 1-7 years of follow-up, with
a 4-year probability of RFS of 76%. Majhail et al re-
ported CB HSCT for MDS in patients age 55 years
and older [47]. All underwent RIC HSCT, using
either an HLA-matched related donor (n 5 47) or
CB (n 5 43; 88% received 2 CB units). With a me-
dian follow-up of 27 months, the 3-year probabilities
of RFS and OS were similar (30% vs 34% and 43%
vs 34%, respectively) [47]. The CIs of grade II-IV
acute GVHD (aGVHD; 42% vs 49%) and day 180
Table 3. Role of GVHD Prophylaxis in Allogeneic HSCT for MDS
Reference n GVHD Prophylaxis Conditioning
TRM, Day
100/1 Year, %
aGVHD
II-IV/III-IV, % cGVHD, % OS, %
Van Besien et al., 2009 [62] 95
59
Tacrolimus
Tacrolimus/MTX
Flu/Mel 140/Campath
Flu/Mel 100-140
11.5/24.6
16.9/28.8
23.3/8.6
58.1/16.5
16
78.4
40.5
45.7
Lim et al., 2006 [63] 75 Cyclosporine Bu/Flu/Campath 8/30 36/26 22 43
Platzbecker et al., 2009 [64] 24 Everolimus/tacrolimus Bu/Flu (n 5 21);
Bu/Cy (n 5 3)
12.5/29 38/18 82% 47
Small et al., 2007 [65] 43 Tacrolimus/MTX Bu/Mel 16 24 38 37
Chan et al., 2003 [66] 18 Cyclosporine/ MTX Photopheresis/pentostatin/TBI 0 19 18 65
GVHD indicates graft-versus-host disease; MDS, myelodysplastic syndrome; MTX, methotrexate; Bu, busulfan; Flu; fludarabine; Mel, melphalan;
Cy, cyclophosphamide; TBI, total body irradiation; TRM, treatment-related mortality, aGVHD, acute graft-versus-host disease; cGVHD, chronic
graft-versus-host disease; OS, overall survival.
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a lower incidence of chronic GVHD (cGVHD) fa-
voring the recipients of CB HSCT (17% vs 40%).
The data on haploidentical HSCT for MDS are lim-
ited. De Witte et al. [34] reported an analysis of 1378
transplantations performed on behalf of the EBMT,
with 91 patients undergoing allogeneic HSCT from ge-
notypically nonidentical related donors. The 3-year sur-
vival and TRM rates were 28% and 66%, respectively,
higher than with any other type of transplantation. In
a more recent series of 28 patients undergoing T cell–
depleted haploidentical HSCT and conditioning with
Flu, melphalan (Mel), thiotepa, and antithymocyte glob-
ulin (ATG), patients with\15% marrow blasts had bet-
ter survival than those with more advanced disease (42%
vs 0; P5 .03), with a day-100 TRM of 9% and a 1-year
TRM of 32% [48].
To summarize, several studies have demonstrated
the long-term curative potential with both related
and unrelated donor allogeneic HSCT in MDS.
Nonetheless, extending allogeneic HSCT to more
patients with MDS will necessarily involve the use of
donors who are not fully matched related or are unre-
lated, given the constraints of donor availability and
procurement. Enrollment in clinical trials will be deci-
sive for the critical evaluation of alternative donor
transplants in this setting.BONE MARROW VERSUS PERIPHERAL
BLOOD CELL GRAFTS
The use of HSCs from peripheral blood (PB) is as-
sociated with faster engraftment and increased cGVHD
rates compared with BM. Retrospective analyses have
suggested that PB is a better stem cell source than BM
for MDS patients undergoing related donor transplan-
tation [49,50]. The survival benefit in those studies
resulted from faster engraftment, lower TRM, and
lower relapse rates (with cGVHD). Guardiola et al.
[51] retrospectively studied 234 MDS patients and com-
pared outcomes after PB and BM HSCT. Significantly
improved 2-year TRM, RFS (50% vs 39%), and treat-
ment failure were observed with PB [51]. As in other dis-
eases and clinical situations, there are insufficientprospective data to clearly guide the choice of stem
cell source, which often is made based on individual
or institutional priorities and perceptions.PREPARATIVE REGIMEN INTENSITY:
CONVENTIONAL-INTENSITY
(MYELOABLATIVE) VERSUS REDUCED-
INTENSITY CONDITIONING
The list of unresolved clinical questions would not
be complete without a discussion of preparative regi-
mens. The choice of conditioning regimen type and
intensity is strongly associated with investigator pref-
erence, experience, and even geographic location! In
the absence of large prospective, randomized studies,
recommendations often are subject to personal or
institutional biases.
In our perception, TBI-based conventional condi-
tioning regimens are being used with decreasing
frequency in patients with MDS. Bu (either with oral
dosing with pharmacokinetic guidance or provided in-
travenously) in combination with cyclophosphamide
(Cy) or Flu is a widely used alternative to TBI [52-54].
The decision to decrease the regimen intensity is not al-
ways straightforward. A lower dose intensity may lead to
higher relapse rates for MDS, in a trade-off with lower
TRM rates. To complicate matters, RIC regimens en-
compass a wide range of combinations, ranging from
the least myeloablative (fludarabine and cyclophospha-
mide or fludarabine and 200 cGy TBI) to regimens that
approach the ‘‘strength’’ of conventional regimens of
cyclophosphamide plus high-dose TBI or busulfan
plus cyclophosphamide. Most reported series com-
bined AML and MDS patients, and often included
transplantations performed with the use of Campath
(alemtuzumab), antithymocyte globulin, or other
GVHD prophylaxis (Table 3), adding more variability
to the mix. In addition, median age and number of
comorbidities usually were higher in the RIC cohorts,
because most patients are selected for dose reduction
on that basis.
In a retrospective analysis of results in 836 patients
(215 receiving RIC and 621 receiving conventional
conditioning), those receiving RIC had a significantly
S42 Biol Blood Marrow Transplant 16:S37-S44, 2010S. Parmar and M. de Limahigher 3-year relapse rate but a significantly lower
TRM [55]. Parker et al. [56] reported that RIC and al-
logeneic sibling or unrelated donor transplantation
was associated with significantly shorter duration of
marrow aplasia, less mucositis and infections, less
need for parenteral nutrition, lower incidence of
aGVHD and cGVHD, and lower TRM (9% vs
31%) compared with HSCT for MDS after conven-
tional-intensity conditioning. The 2-year actuarial
OS and RFS was 48% and 39%, respectively, in the
RIC group, and 44% and 44% in the conventional
group, with a respective TRM of 31% and 50%. In un-
related donor transplant recipients, OS was superior in
the RIC arm (49% vs 34%) [56]. Others have reported
similar outcomes after conventional-conditioning and
RIC transplantations in retrospective studies [57,58].
Our bias is to recommend the highest dose intensity
that a patient is expected to be able to tolerate, which
often is difficult to judge. When age is the sole deter-
mining factor, we offer high-dose Flu and single daily
dose of i.v. Bu to patients up to age 60-65 years [53].
Bu, this recommendation is subject to the biases and
limitations discussed earlier, and at this time there are
insufficient data to make a recommendation for optimal
conditioning regimen intensity. Patients in their early
60s who are fit (other than their MDS) are now eligible
for conventional-intensity conditioning regimens in
our institution and elsewhere, but the controversy sur-
rounding dose intensity will not be resolved without
randomized prospective studies [59]. Older patients
and those with comorbidities who are candidates for al-
logeneic HSCT should be considered for RIC regi-
mens, and as in all of the aforementioned scenarios,
should be enrolled in clinical trials.
FUTURE DIRECTIONS
We believe that pharmacologic or immunologic
interventions after HSCT should be investigated. Im-
proved integration of pretransplantation treatments
and the preparative regimen is likely to play an impor-
tant role in the overall management of patients with
MDS [60]. The incorporation of newer drugs into
the conditioning regimen, as investigated by several
groups, may lead to improved antileukemic efficacy.
As discussed, defining the roles of CB and haploident-
ical HSCT likely will make an important contribution.ACKNOWLEDGMENTS
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